SAT0173 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: result from the long-term treatment of phase 3, desirable study

Abstract

Background:Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival. The effect of denosumab on...